Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643208 | 1.00 | KDR (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL29723905 | 1.00 | KDR (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL7990375 | 0.89 | KDR (0.84) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL28036432 | 0.87 | GAA (0.66) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL28871825 | 0.87 | GAA (0.58) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL259290 | 0.84 | RAB9A (0.69) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12197847 | 0.84 | GRM4 (0.76) | KDRGRM4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29496401 | 0.83 | GRM4 (1.00) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL2528081 | 0.83 | GRM4 (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL2530324 | 0.83 | GRM4 (1.00) | KDRGRM4HDAC6KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047879-B | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2022-01-14 | — | — | CN | disclosed |
| CN-112047879-A | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2020-12-08 | — | — | CN | disclosed |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| WO-2017184589-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-26 | — | — | WO | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | KDR 628/4885GRM4 3432/4885HDAC6 191/4885 |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | AHR, PAH, DOHH | KDR 1117/4885GRM4 1333/4885HDAC6 860/4885 |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | PAH, AHR, DDC | KDR 782/4885GRM4 2325/4885HDAC6 1082/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | KDR 628/4885GRM4 3432/4885HDAC6 191/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | KDR 628/4885GRM4 3432/4885HDAC6 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.